BCL-XL drives fibrotic and leukemic progression in myeloproliferative neoplasms
Authors:
Open Access
- 2 June 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1818806
Abstract
Background: Myeloproliferative neoplasms (MPNs) are frequently accompanied by bone marrow fibrosis and leukemic transformation, yet the cellular and molecular mechanisms that sustain apoptosis resistance and fibrotic progression remain unclear. Methods: Bone marrow mesenchymal stromal cells (BM-MSCs) from patients with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) were analyzed for fibrotic phenotype, apoptosis signaling, and pathway activation using cell counting kit-8, immunofluorescence, flow cytometry, western blotting, hydroxyproline and transmission electron microscopy. The cytotoxic and antifibrotic effects of the BCL-XL inhibitor ABT-263 (navitoclax), alone or combined with the JAK2 inhibitor ruxolitinib, were evaluated in stromal and hematopoietic contexts. Results: BCL-XL was markedly upregulated in JAK2-driven disease and predominated over other BCL-2 family members in both malignant hematopoietic cells and fibrotic stromal compartments. MSCs derived from MPN patients exhibited a myofibroblast-like phenotype characterized by increased α-smooth muscle actin (α-SMA) and fibronectin (FN) expression. Pharmacologic inhibition of BCL-XL with ABT-263 selectively induced mitochondrial apoptosis in PMF-derived MSCs and attenuated their profibrotic features. Mechanistically, transforming growth factor β (TGF-β) activated both SMAD3 and STAT3 signaling in MSCs, indicating cooperative engagement of TGF-β/SMAD3 and JAK2/STAT3 pathways in stromal fibrotic activation. Combined inhibition of BCL-XL and JAK2 produced synergistic antifibrotic and pro-apoptotic effects in MSCs, post-MPN acute myeloid leukemia (AML) cell lines, and patient-derived cells resistant to ruxolitinib. Conclusion: Collectively, these findings identified BCL-XL as a key mediator of MPN-associated fibrosis and therapeutic resistance, and confirmed dual targeting of BCL-XL and JAK2 as a rational strategy for advanced MPN.Keywords
This publication has 41 references indexed in Scilit:
- Therapeutic potential of stem cells in regeneration of liver in chronic liver diseases: Current perspectives and future challengesPharmacology & Therapeutics, 2023
- New era for myelofibrosis treatment with novel agents beyond Janus kinase‐inhibitor monotherapy: Focus on clinical development of BCL‐XL/BCL‐2 inhibition with navitoclaxCancer, 2023
- Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signalingMolecular Therapy Nucleic Acids, 2023
- Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategiesMolecular Aspects of Medicine, 2023
- JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XLMolecular Oncology, 2023
- Yangqing Chenfei formula attenuates silica-induced pulmonary fibrosis by suppressing activation of fibroblast via regulating PI3K/AKT, JAK/STAT, and Wnt signaling pathwayPhytomedicine, 2022
- Blockade of the TGF-β pathway by galunisertib inhibits the glial-mesenchymal transition in Müller glial cellsExperimental Eye Research, 2022
- Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axisCell Stem Cell, 2021
- Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformationCellular Signalling, 2011
- Leukemic transformation of polycythemia veraCancer, 2005